Drug Type Small molecule drug |
Synonyms BI 764198, BI-764198, BI764198 |
Target |
Mechanism TRPC6 antagonists(transient receptor potential cation channel subfamily C member 6 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Kidney Diseases | Phase 2 | US | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | CN | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | AU | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | BE | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | FR | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | DE | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | IT | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | NZ | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | ES | 10 Mar 2022 | |
Chronic Kidney Diseases | Phase 2 | GB | 10 Mar 2022 |
Phase 2 | 133 | (BI 764198 Treatment Group) | dxthawkayd(usvzehciit) = ngzkzaoenc idnfsbkxay (picsqsrlfj, scdtrbsbpt - tpguskdrts) View more | - | 11 Apr 2022 | ||
Placebo (Placebo) | dxthawkayd(usvzehciit) = lewjflgran idnfsbkxay (picsqsrlfj, iryxzzgkzc - eiiwbfzdkd) View more |